SPH-4336: A Comprehensive Clinical and Strategic Analysis of a Novel CDK4/6 Inhibitor

Executive Summary

SPH-4336 is an investigational, orally bioavailable small molecule inhibitor of cyclin-dependent kinase types 4 and 6 (CDK4/6), being developed by Shanghai Pharmaceuticals Holding Co., Ltd..[1] As a member of a well-established therapeutic class, SPH-4336 aims to provide a new option for the treatment of various solid tumors by targeting the fundamental cell cycle machinery often dysregulated in cancer. The drug's development program is underpinned by promising preclinical activity and has progressed into human clinical trials, with the most comprehensive data emerging from a first-in-human Phase I study (NCT05905614).

This foundational study in 29 patients with advanced solid tumors established a favorable safety profile, where no dose-limiting toxicities (DLTs) were observed up to the highest tested dose of 600 mg once daily.[3] The maximum tolerated dose (MTD) was not reached, suggesting a broad therapeutic window. However, the drug is associated with a high incidence of treatment-related adverse events (TRAEs), with 100% of patients experiencing at least one, and 51.7% experiencing events of Grade 3 or higher, primarily manageable hematologic and gastrointestinal toxicities.[3] Pharmacokinetic analysis identified 400 mg once daily as the recommended Phase II dose (RP2D), based on evidence of absorption saturation at higher doses.[3]

Preliminary efficacy signals from the Phase I trial are encouraging, highlighted by an overall disease control rate (DCR) of 59.3% and evidence of durable clinical benefit, with some patients with breast cancer and sarcoma achieving a progression-free survival (PFS) exceeding six months.[3] These early findings support the developer's dual-pronged clinical strategy. The first prong involves challenging the established blockbuster therapies in the large, competitive hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer market.[5] The second, more distinct prong, targets the high unmet medical need in advanced liposarcoma, an indication for which SPH-4336 has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), potentially offering a faster path to market.[5] SPH-4336's future will be defined by its ability to navigate these distinct strategic paths, balancing the high-risk, high-reward breast cancer landscape against the more targeted, niche opportunity in liposarcoma.

Drug Profile and Mechanism of Action

Chemical and Pharmacological Classification

SPH-4336 is classified as an orally bioavailable, small molecule inhibitor with potential antineoplastic activity.[1] It is identified by the code names SPH 4336 and SPH4336.[1]

The full chemical name for the compound is N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine.[6] Its chemical formula is

C31​H34​F2​N8​O4​, and it is registered under CAS Number 2765997-88-2.[6] The drug is administered as a tablet for oral use.[8]

The CDK4/6-Retinoblastoma (Rb) Pathway in Oncology

The inhibition of cyclin-dependent kinases (CDKs) represents a highly validated and attractive strategy for the development of modern anticancer drugs.[3] Specifically, CDK4 and CDK6 are serine/threonine kinases that serve as critical regulators of cell cycle progression.[1] In normal cellular function, the activity of CDK4 and CDK6 is tightly controlled. When stimulated by D-type cyclins, these kinases form active complexes that phosphorylate a key tumor suppressor, the retinoblastoma protein (Rb).[1]

Phosphorylation of Rb causes it to release its inhibitory grip on the E2F family of transcription factors. Once liberated, E2F proteins activate the transcription of genes necessary for DNA replication and cell cycle progression, thereby enabling the cell to transition from the G1 (first growth) phase into the S (DNA synthesis) phase.[1] In many types of cancer, this CDK4/6-Rb pathway is dysregulated, often through the overexpression of cyclins or the loss of natural CDK inhibitors, leading to uncontrolled phosphorylation of Rb and perpetual cell proliferation. This frequent upregulation in tumor cells makes the CDK4/6 enzymes prime therapeutic targets.[1]

SPH-4336's Molecular Target Engagement

SPH-4336 functions as a selective inhibitor of both CDK4 and CDK6.[1] Upon oral administration, the molecule targets and binds to these kinases, blocking their enzymatic activity. This direct inhibition prevents the phosphorylation of the Rb protein early in the G1 phase of the cell cycle.[1] By maintaining Rb in its active, hypophosphorylated state, SPH-4336 effectively enforces the G1 restriction point, leading to cell cycle arrest. This halt in progression prevents the cell from entering the S phase, which suppresses DNA replication and ultimately curtails tumor cell proliferation.[1]

The developer, Shanghai Pharmaceuticals, has positioned SPH-4336 as a novel inhibitor with "high selectivity and improved inhibition" for CDK4/6.[3] This claim is a critical element of the drug's value proposition. In a mature market dominated by three highly successful CDK4/6 inhibitors, a new entrant must offer a distinct advantage to gain clinical and commercial traction.[9] Claims of "improved inhibition" or "high selectivity" are strategic declarations that suggest the potential for a superior therapeutic window. For example, increased selectivity for CDK4 over CDK6 has been explored by other developers as a strategy to potentially mitigate neutropenia, a common class effect, while enhanced potency could translate to greater anti-tumor activity.[9] This positioning sets a high standard for SPH-4336, implying an ambition to be a best-in-class, rather than a "me-too," agent. The validity of this assertion will ultimately be determined by the full body of clinical data as it emerges.

Clinical Development Program Overview

Preclinical Evidence and Rationale for Development

The advancement of SPH-4336 into human trials was predicated on preclinical studies that demonstrated promising anti-tumor activity.[3] This foundational research provided the necessary evidence of biological effect to justify clinical investigation. A particularly significant finding from this preclinical work was the observation of "significant antitumor effects in nude mouse subcutaneous graft models of clinically patient-derived liposarcoma PDX".[5] This specific result, showing efficacy in patient-derived xenograft models, is a strong indicator of potential clinical relevance and provides a direct scientific rationale for the strategic decision to pursue liposarcoma as a key indication in the clinical development program.

Summary of Clinical Trials

The clinical development program for SPH-4336 is structured to evaluate its safety, pharmacokinetics, and efficacy as both a monotherapy and in combination with other agents across a range of solid tumors. The program has progressed from an initial first-in-human study to later-phase trials in specific, strategically chosen indications.

Table 1: Overview of SPH-4336 Clinical Trials
Trial Identifier	Phase	Title/Indication	Study Design	Status	Sponsor
NCT05905614	Phase 1	Advanced Solid Tumors	First-in-human, dose-escalation and -expansion	Completed	Shanghai Pharmaceuticals Holding Co., Ltd.
NCT05580588	Phase 2	Locally Advanced or Metastatic Liposarcomas	Open-label, single-arm	Recruiting	Shanghai Pharma Biotherapeutics USA Inc.
Not specified	Phase 3	HR+/HER2- Metastatic Breast Cancer (in combination with letrozole)	Randomized, placebo-controlled	Recruiting	Shanghai Pharmaceuticals Holding Co., Ltd.
NCT05944224	Phase 1b/2a	Advanced Solid Tumors (including Liposarcoma) (monotherapy or in combination with Cadonilimab)	Randomized, open-label, parallel assignment	Recruiting	Shanghai Pharmaceuticals Holding Co., Ltd.
	2

Strategic Focus on Key Indications

The clinical trial portfolio reveals a sophisticated and deliberate dual-pronged development strategy designed to maximize the potential for regulatory approval and commercial success.

The first prong is a high-risk, high-reward approach targeting the large and well-established HR+/HER2- breast cancer market. By initiating a Phase III trial of SPH-4336 in combination with letrozole, Shanghai Pharmaceuticals is directly challenging the three blockbuster drugs that define the current standard of care: palbociclib, ribociclib, and abemaciclib.[2] Success in this arena would grant access to a multibillion-dollar market but requires demonstrating a compelling clinical advantage over entrenched competitors, a significant hurdle for any new agent.

The second prong represents a more targeted, de-risked strategy focused on becoming a market leader in a niche indication with high unmet need. The focus on advanced liposarcoma is supported by strong preclinical data and the absence of any currently approved CDK4/6 inhibitor for this disease.[5] This approach is significantly bolstered by the FDA's granting of Orphan Drug Designation, which provides regulatory incentives and a clearer path to potential approval.[5]

This parallel pursuit of a broad market and a niche indication constitutes a well-designed hedge against development risk. A successful outcome in liposarcoma could provide an earlier-to-market approval, generating an initial revenue stream and validating the drug's clinical activity. This success could, in turn, support the more costly and competitive development in breast cancer. Even if the breast cancer trial fails to demonstrate superiority over existing therapies, an approval in liposarcoma would ensure the asset is not a complete loss, thereby securing a return on investment.

In-Depth Analysis of the First-in-Human Phase I Trial (NCT05905614)

The first-in-human Phase I trial, NCT05905614, provides the most comprehensive clinical dataset for SPH-4336 to date. Its findings on safety, pharmacokinetics, and preliminary efficacy are foundational to the drug's entire development program.[3]

Study Design and Patient Population

This was a multicenter, open-label, Phase I study employing a dose-escalation and dose-expansion design.[3] The primary objective was to assess the safety and tolerability of SPH-4336 and to determine its MTD and any DLTs.[3]

A total of 29 patients were enrolled across four hospitals in China between November 2020 and February 2023.[4] The study population consisted of patients with histologically or cytologically confirmed advanced solid tumors that were refractory or intolerant to standard treatment, or for which no standard therapy existed.[3] Key demographics included a median age of 55.0 years (range: 23–66) and a predominance of female patients (72%).[3] The most represented tumor types were breast cancer, accounting for nearly half of the cohort (n=14, 48.3%), and sarcoma (n=8, 27.6%), aligning with the drug's strategic development focus.[3]

The dose-escalation phase followed a standard 3+3 design, evaluating six once-daily oral dose cohorts: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 600 mg.[3]

Safety and Tolerability Profile

A primary outcome of the study was that no DLTs were observed across any dose cohort, and consequently, the MTD was not reached up to the highest planned dose of 600 mg.[3] This finding suggests that the drug does not cause unacceptable acute toxicity within the defined DLT observation window.

However, the absence of DLTs must be interpreted alongside the high overall incidence of adverse events. All 29 patients (100%) experienced at least one TRAE.[3] While most of these were Grade 1 or 2, a significant portion of patients—15 out of 29 (51.7%)—experienced Grade 3 or higher TRAEs.[4] No Grade 4 TRAEs were reported, and the single death on study was due to disease progression and considered unrelated to SPH-4336.[3]

The most common toxicities were consistent with the known class effects of CDK4/6 inhibitors, primarily involving myelosuppression and gastrointestinal issues.

Table 2: Summary of All-Grade Treatment-Related Adverse Events (TRAEs) Occurring in ≥10% of Patients (N=29)
Adverse Event	Frequency (n)	Percentage (%)
White Blood Cell Count Decreased	21	72.4
Diarrhea	20	69.0
Neutrophil Count Decreased	19-20	65.5 - 69.0
Anemia	18-19	62.1 - 65.5
Vomiting	12	41.4
Abdominal Pain	9	31.0
Nausea	9	31.0
	3

The clinically significant Grade 3 toxicities were predominantly hematologic.

Table 3: Incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs) (N=29)
Adverse Event	Frequency (n)	Percentage (%)
Decreased Leucocyte Count	4	13.8
Decreased Lymphocyte Count	4	13.8
Decreased Neutrophil Count	3	10.3
	4

The study's conclusion that SPH-4336 was "well tolerated" despite these high rates of toxicity highlights a critical distinction in oncologic drug development.[3] "Tolerability" in the context of a Phase I trial is primarily defined by the absence of DLTs, which are severe, often irreversible, or life-threatening toxicities that preclude further dose escalation. The adverse events observed with SPH-4336, while frequent and in many cases severe (Grade 3), were considered predictable, manageable with supportive care or dose modifications, and did not meet the stringent, protocol-defined criteria for a DLT. This profile indicates that SPH-4336 has substantial on-target biological activity leading to toxicity (e.g., myelosuppression), but this toxicity was deemed clinically manageable. This implies that its successful use in broader patient populations will depend heavily on proactive monitoring and established protocols for managing its side effect profile.

Pharmacokinetic (PK) Profile and Dose Determination

Pharmacokinetic assessments were crucial in defining the optimal dose for future studies. The data revealed that plasma exposure to SPH-4336 increased in a dose-dependent manner in cohorts ranging from 50 mg to 400 mg.[3] However, a critical finding was that at the 600 mg dose level, plasma concentrations did not increase further.[3] This plateau in exposure suggests that the drug's absorption mechanism becomes saturated at or around the 400 mg dose.

This PK profile provides a robust, data-driven rationale for the selection of the RP2D. Increasing the dose from 400 mg to 600 mg offers no additional therapeutic benefit in terms of systemic drug exposure but could increase the risk of toxicity. Indeed, the only drug-related serious adverse event (a Grade 3 increase in γ-glutamyl transferase) occurred in the 600-mg cohort.[4] The study also determined that at the 400 mg dose, SPH-4336 reached a steady state in plasma after two weeks of continuous daily administration.[3]

Based on the totality of the safety, preliminary efficacy, and particularly the PK data, 400 mg once daily was established as the RP2D for subsequent clinical trials.[3] This represents a scientifically sound conclusion from the Phase I study, identifying the dose that maximizes drug exposure with an acceptable and manageable safety profile.

Preliminary Efficacy Assessment

While the primary goal of a Phase I study is to assess safety, preliminary signals of anti-tumor activity are vital for guiding future development. Among the 27 patients evaluable for efficacy, SPH-4336 demonstrated clear biological activity.[3]

One patient with breast cancer, treated in the 600-mg cohort, achieved a confirmed Partial Response (PR), with tumor shrinkage lasting for 169 days (5.6 months).[3] While the overall objective response rate (ORR) was modest at 3.7%, this is not unexpected in a heterogeneous, heavily pre-treated Phase I population.[4]

A more telling indicator of the drug's activity was the DCR. Fifteen patients (55.6%) achieved stable disease (SD) as their best response, leading to an overall DCR (PR + SD) of 59.3% (95% CI: 38.8%-77.6%).[3] This indicates that a majority of patients derived some measure of disease stabilization from the treatment. Furthermore, regression of target lesions from baseline was noted in patients treated at the 100 mg, 400 mg, and 600 mg dose levels, suggesting a dose-related anti-tumor effect.[3]

Perhaps the most compelling efficacy signal was the durability of benefit observed in a subset of patients. The study reported that PFS exceeded 6 months in six patients, specifically those with breast cancer and sarcoma.[4] In the context of an early-phase trial with patients who have exhausted standard options, achieving durable disease control for over half a year is a highly meaningful clinical outcome. This finding is more significant than the low ORR, as it suggests that for appropriately selected patients, SPH-4336 can provide prolonged clinical benefit. This signal of durable activity provides strong validation for the sponsor's strategic decision to pursue pivotal trials in these two specific histologies.

Table 4: Summary of Efficacy Outcomes in the Phase I Trial (N=27 evaluable patients)
Efficacy Parameter	Value
Objective Response Rate (ORR)	3.7% (95% CI: 0.1%-19.0%)
Partial Response (PR)	1 patient (3.7%)
Stable Disease (SD)	15 patients (55.6%)
Disease Control Rate (DCR)	59.3% (95% CI: 38.8%-77.6%)
Median Progression-Free Survival (PFS)	3.1 months (95% CI: 1.7-5.7)
	3

Strategic and Competitive Landscape

Regulatory Status: FDA Orphan Drug Designation for Liposarcoma

A significant milestone in the development of SPH-4336 was achieved on March 28, when the U.S. FDA granted it Orphan Drug Designation for the treatment of liposarcoma.[5] This designation is conferred upon drugs intended to treat rare diseases or conditions affecting fewer than 200,000 individuals in the United States.[5]

This status provides substantial regulatory and commercial advantages that can accelerate the drug's development and enhance its market potential. Benefits include a potential seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and the waiver of certain FDA fees, such as the Prescription Drug User Fee.[5] Critically, it is noted that no other product targeting CDK4/6 has been approved by the FDA for liposarcoma, positioning SPH-4336 as a potential first-in-class agent for this indication.[5] However, this advantageous position is not guaranteed; if another company secures approval for an identical drug in the same indication first, SPH-4336 would lose its orphan drug benefits unless it can demonstrate clinical superiority.[5] This creates a time-sensitive imperative to advance the liposarcoma program efficiently.

Comparative Analysis with Approved CDK4/6 Inhibitors

The ultimate success of SPH-4336, particularly in breast cancer, will depend on its differentiation from the three approved blockbuster CDK4/6 inhibitors: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio).[9] A comparative analysis based on available data reveals key similarities and potential differences.

Table 5: Comparative Profile of SPH-4336 vs. Approved CDK4/6 Inhibitors
Feature	SPH-4336 (Emerging Data)	Palbociclib (Ibrance)	Ribociclib (Kisqali)	Abemaciclib (Verzenio)
Dosing Schedule	Continuous once daily	21 days on / 7 days off	21 days on / 7 days off	Continuous twice daily
Administration with Food	Not specified (oral tablet)	Capsules with food; Tablets with or without food	With or without food	With or without food
Key Hematologic AEs (Incidence of Grade 3/4 Neutropenia)	10.3% (Grade ≥3 Neutrophil Count Decreased)	~66%	~60%	~22-32%
Key Non-Hematologic AEs (Incidence of Grade 3 Diarrhea)	Not specified (69.0% all-grade)	~2%	~1%	~13-20%
Other Clinically Relevant AEs	Not specified	ILD/Pneumonitis, Venous Thromboembolism	QTc Prolongation, Hepatotoxicity, ILD/Pneumonitis	Diarrhea, Hepatotoxicity, Venous Thromboembolism, ILD/Pneumonitis
	3

This comparison reveals a potentially challenging "hybrid" toxicity profile for SPH-4336. The CDK4/6 inhibitor class is often differentiated by dominant toxicities: palbociclib and ribociclib are primarily associated with high rates of neutropenia, while abemaciclib is known for causing significant diarrhea.[11] The Phase I data for SPH-4336, however, shows a high incidence of both myelosuppression (72.4% all-grade decreased white blood cell count) and gastrointestinal toxicity (69.0% all-grade diarrhea).[3]

While the reported rate of Grade 3 neutropenia (10.3%) appears lower than that of palbociclib and ribociclib, the all-grade rates of both key toxicities are very high. If this profile persists in larger trials, it could present a clinical management challenge. Physicians are accustomed to proactively managing one primary side effect for each agent (e.g., monitoring blood counts for palbociclib, providing anti-diarrheals for abemaciclib). A drug that requires simultaneous, intensive management of both high-grade neutropenia and frequent diarrhea could be perceived as more complex to use. This places a greater burden on SPH-4336 to demonstrate a compelling efficacy advantage in its pivotal trials to outweigh a potentially less favorable safety and management profile.

Emerging Therapeutic Combinations and Future Directions

Shanghai Pharmaceuticals is actively exploring the future of SPH-4336 beyond its initial monotherapy and endocrine combination trials. The development strategy includes investigating novel combinations aimed at enhancing efficacy and overcoming resistance. The ongoing Phase III trial combines SPH-4336 with the aromatase inhibitor letrozole, a standard-of-care backbone in HR+/HER2- breast cancer.[2]

More innovatively, the company has entered into a collaboration with Kangfang Pharmaceutical to evaluate SPH-4336 in combination with cadonilimab (Kaitanil).[5] Cadonilimab is a bispecific antibody targeting both PD-1 and CTLA-4. The Phase Ib/IIa trial (NCT05944224) will assess this combination in patients with advanced solid tumors, including liposarcoma.[13] This move into the immuno-oncology space is strategically significant. Preclinical evidence has suggested that CDK4/6 inhibitors can enhance tumor cell immunogenicity, providing a strong rationale for combining them with immune checkpoint inhibitors.[9] This forward-looking approach indicates an intent not only to compete with the current standard of care but also to help define the next generation of combination therapies in these diseases.

Expert Assessment and Outlook

Synthesis of Key Findings

SPH-4336 has emerged from early-phase clinical development as a novel CDK4/6 inhibitor with a well-defined pharmacological profile and clear signals of clinical activity. Its foundational Phase I trial successfully established a recommended Phase II dose of 400 mg once daily, guided by robust pharmacokinetic data showing absorption saturation at higher doses. The drug's safety profile is characterized by manageable, albeit frequent and sometimes severe, on-target toxicities, primarily myelosuppression and diarrhea. Critically, the absence of dose-limiting toxicities suggests a workable therapeutic index. The preliminary efficacy data, particularly the 59.3% disease control rate and evidence of durable progression-free survival in patients with breast cancer and sarcoma, provides a solid foundation for its ongoing and future pivotal trials.

Potential Strengths and Weaknesses

The development program for SPH-4336 possesses distinct strengths and faces significant challenges that will shape its future trajectory.

Strengths:

• Clear Path in a Niche Indication: The development path in advanced liposarcoma is the drug's most compelling asset. It is supported by strong, specific preclinical data, addresses a high unmet medical need, and benefits from the considerable regulatory and commercial advantages conferred by its FDA Orphan Drug Designation. This provides a clear and potentially rapid route to an initial market approval.
• Robust Foundational Clinical Data: The Phase I trial was well-conducted, yielding a clear, data-driven RP2D and unambiguous signals of durable clinical benefit in the two key target populations. This de-risks the decision to proceed with more expensive later-phase studies.

Weaknesses/Challenges:

• Intense Competition in Breast Cancer: The HR+/HER2- breast cancer market is one of the most competitive arenas in oncology. SPH-4336 must contend with three entrenched, blockbuster competitors, each supported by vast datasets and years of real-world physician experience.
• Potentially Unfavorable "Hybrid" Safety Profile: The high incidence of both hematologic and gastrointestinal toxicities could make SPH-4336 more challenging to manage in a clinical setting compared to competitors with more singular toxicity profiles. This could be a significant barrier to adoption unless offset by superior efficacy.
• High Efficacy Bar for Market Entry: To capture meaningful market share in breast cancer, SPH-4336 will need to demonstrate not just non-inferiority, but a clinically meaningful advantage over the existing standards of care, a very high bar to clear.

Critical Development Hurdles and Future Outlook

The future of SPH-4336 appears to be bifurcated. The most promising and straightforward path to its first approval lies in the liposarcoma indication. Executing the Phase II trial (NCT05580588) efficiently and achieving a positive outcome is the most critical near-term hurdle. Success here would validate the drug, establish a commercial foothold, and provide momentum for the broader program.

The outlook in breast cancer is considerably more challenging and uncertain. The success of this program is entirely contingent on the results of the ongoing Phase III trial. The central question is whether SPH-4336 can deliver an efficacy benefit substantial enough to convince clinicians and payers to adopt a new agent with a potentially more complex safety profile.

Finally, the exploration of immuno-oncology combinations is a strategically astute, forward-looking initiative that could unlock significant long-term value, particularly if resistance to standard CDK4/6 inhibitor-endocrine therapy combinations continues to grow. However, this remains a longer-term prospect. The immediate fate of SPH-4336 rests on the flawless execution of its pivotal registration trials in liposarcoma and breast cancer.

Works cited

1. Definition of CDK4/6 inhibitor SPH4336 - NCI Drug Dictionary, accessed September 6, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cdk4-6-inhibitor-sph4336
2. SPH4336 / Shanghai Pharma - Larvol Delta, accessed September 6, 2025, https://delta.larvol.com/Products/?ProductId=341b4b4f-16a9-4bec-a737-9d32eace354a
3. First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors. - ASCO Publications, accessed September 6, 2025, https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.e15107
4. Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 ..., accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12207880/
5. Received orphan drug recognition! Shanghai Pharmaceutical SPH4336 breakthrough liposarcoma - Echemi, accessed September 6, 2025, https://www.echemi.com/cms/1313710.html
6. SPH-4336 | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/salts/DBSALT003438
7. SPH-4336 - gsrs, accessed September 6, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9X8U786V5T
8. Likelihood of Approval and Phase Transition Success Rate Model – SPH-4336 in Dedifferentiated Liposarcoma - GlobalData, accessed September 6, 2025, https://www.globaldata.com/store/report/sph-4336-in-dedifferentiated-liposarcoma-loa-innovation-and-trend-analysis/
9. CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire, accessed September 6, 2025, https://www.prnewswire.com/news-releases/cdk46-inhibitors-market-to-grow-at-healthy-growth-rate-by-2034-owing-to-expanded-usage-of-approved-blockbuster-cdk46-inhibitors-in-early-stage-breast-cancer-and-the-emergence-of-newer-players-in-other-indications--delveinsight-302274816.html
10. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With ..., accessed September 6, 2025, https://www.mayo.edu/research/clinical-trials/cls-20548701
11. The First-Of-Its-Kind In The Treatment Of HR+/HER2- Metastatic Breast Cancer - IBRANCE.com, accessed September 6, 2025, https://www.ibrance.com/about-ibrance
12. HR+, HER2- Early and Metastatic Breast Cancer Treatment | Verzenio® (abemaciclib), accessed September 6, 2025, https://verzenio.lilly.com/
13. A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | ClinicalTrials.gov, accessed September 6, 2025, https://clinicaltrials.gov/study/NCT05944224
14. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas - NCI, accessed September 6, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-04261
15. First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors. - ASCO Publications, accessed September 6, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e15107
16. full prescribing information for IBRANCE - Pfizer, accessed September 6, 2025, https://labeling.pfizer.com/showlabeling.aspx?id=2191
17. IBRANCE® (palbociclib) Dosing & Administration | Safety Info, accessed September 6, 2025, https://ibrance.pfizerpro.com/dosing/administration
18. Dosing & Administration | mBC - KISQALI® (ribociclib), accessed September 6, 2025, https://us.kisqali.com/metastatic-breast-cancer/about-kisqali/how-to-take-kisqali
19. KISQALI | Novartis, accessed September 6, 2025, https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf
20. Verzenio (abemaciclib) dosing, indications, interactions, adverse effects, and more, accessed September 6, 2025, https://reference.medscape.com/drug/verzenio-abemaciclib-1000194
21. Verzenio® (abemaciclib) for Health Care Professionals - Eli Lilly, accessed September 6, 2025, https://verzenio.lilly.com/hcp